Pro Variant of TP53 Arg72Pro Contributes to Gastric Cancer Risk in Asians: Evidence from a Meta-analysis

Xiu-Li Su,Jianjun Jia

doi:10.7314/apjcp.2012.13.3.915

Abstract

Previous studies investigating the association between TP53 Arg72Pro polymorphism and gastric cancer (GC) risk in Asian population have reported controversial results. Thus, a meta-analysis was performed. A comprehensive literature search was conducted and 17 case-control studies were finally included, involving a total of 5,990 GC cases and 6,812 controls. Subgroup analyses were performed by the sample size. Meta-analysis of all 17 studies showed variant genotypes of TP53 Arg72Pro to be associated with an elevated GC risk in three genetic comparison models (OR(Pro vs. Arg)=1.13, 95%CI 1.03-1.25, P(OR)=0.01; OR(Homozygote comparison model)=1.33, 95%CI 1.07-1.64, P(OR)=0.009; OR(Dominant genetic model)=1.13, 95%CI 1.05-1.22, P(OR)=0.002). Besides, a more obvious association was observed after the heterogeneity was decreased (all P values less than 0.001). This association was further identified by both subgroup and sensitivity analyses. This meta-analysis suggests the Pro variant of TP53 Arg72Pro contributes to gastric cancer risk in Asians.

Highlights

Gastric cancer (GC) was the sixth most common cancer worldwide (989,600 new cancer cases) and the second most frequent cause of cancer death worldwide (738,000 cancer deaths) in 2008 (Jemal et al, 2011)
Previous studies investigating the association between TP53 Arg72Pro polymorphism and gastric cancer (GC) risk in Asian population have reported controversial results
Meta-analysis of all 17 studies showed variant genotypes of TP53 Arg72Pro to be associated with an elevated GC risk in three genetic comparison models (ORPro vs. Arg =1.13, 95%confidence interval (CI) 1.03-1.25, POR=0.01; ORHomozygote comparison model =1.33, 95%CI 1.07-1.64, POR=0.009; ORDominant genetic model =1.13, 95%CI 1.05-1.22, POR=0.002)

Summary

Introduction

Gastric cancer (GC) was the sixth most common cancer worldwide (989,600 new cancer cases) and the second most frequent cause of cancer death worldwide (738,000 cancer deaths) in 2008 (Jemal et al, 2011). Over 70% of new cases and deaths occur in developing countries, and the highest incidence rate is in Eastern Asia (Jemal et al, 2011). Several large scale casecontrol studies have been published to further assess the association between TP53 Arg72Pro and GC risk in Asian population, which is the highest incidence rate of GC, but the association above in Eastern Asia is still uncertain (Kim et al, 2010; Shirai et al, 2010; Song et al, 2011). To assess the evidence regarding the association TP53 Arg72Pro and GC risk and to investigate potential sources of heterogeneity, we conducted a comprehensive meta-analysis of epidemiological studies investigating this association

Materials and Methods

Results

Data not available